IP Library Granted Patent US 11,434,295
Granted Patent B2
US 11,434,295 · App. 13/294,103 · Granted Sep 6, 2022

Methods and compositions for inhibiting CD32B expressing cells

Inventors: Seung Yup Chu (Cypress, CA); John R. Desjarlais (Pasadena, CA); Sher Bahadur Karki (Pomona, CA); Gregory Alan Lazar (Arcadia, CA); Gregory L. Moore (Monrovia, CA); Igor Vostiar (Monrovia, CA)
Assignee: XENCOR, INC.
C07K16/283C07K16/00C07K16/2803C07K16/2851C07K16/2878A61K2039/505C07K2317/24C07K2317/31C07K2317/52C07K2317/524C07K2317/53C07K2317/71C07K2317/72C07K2317/73C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,434,295
App. No.
13/294,103
Granted
Sep 6, 2022
Kind
B2
Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

Claims (11)

1. A method of inhibiting at least one B cell, comprising contacting the cell with an antibody that binds to CD19,

wherein the antibody comprises a light chain variable region comprising SEQ ID NO: 1 and a heavy chain variable region comprising SEQ ID NO: 2, and

an Fc region comprising an amino acid substitution S267E,

wherein the numbering is according to the EU index, as in Kabat.

2. The method according to claim 1 , wherein the antibody further comprises an amino acid substitution L328F in the Fc region of the antibody.

3. A method of inhibiting at least one B cell, comprising contacting the cell with an antibody comprising:

a) a light chain variable region comprising SEQ ID NO: 1;

b) a heavy chain variable region comprising SEQ ID NO: 2; and

c) a variant Fc human IgG1 domain comprising the amino acid substitution S267E, wherein the numbering is according to the EU index as in Kabat.

4. The method according to claim 3 , wherein the variant Fc human IgG1 domain of the antibody further comprises an amino acid substitution L328F.

5. The method according to claim 3 , wherein the variant Fc human IgG1 domain of the antibody consists of amino acid substitutions S267E and L328F in the Fc region.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2011
From: CHU, SEUNG YUP; DESJARLAIS, JOHN R.; KARKI, SHER BAHADUR; LAZAR, GREGORY ALAN; MOORE, GREGORY L.; VOSTIAR, IGOR
To: XENCOR, INC.
Reel/Frame 027350/0116 →
Continuity (13)
Division 12156183 · May 30, 2008
Provisional Application 60940776 · May 30, 2007
Provisional Application 60953174 · Jul 31, 2007
Provisional Application 60970413 · Sep 6, 2007
Provisional Application 60976279 · Sep 28, 2007
Provisional Application 60990509 · Nov 27, 2007
Provisional Application 61012035 · Dec 6, 2007
Provisional Application 61013775 · Dec 14, 2007
Provisional Application 61019395 · Jan 7, 2008
Provisional Application 61032059 · Feb 27, 2008
Provisional Application 61043585 · Apr 9, 2008
Provisional Application 61046397 · Apr 18, 2008
Related Publication 20120156207A1 · Jun 21, 2012